VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment

Patients with cancer who receive an immune checkpoint inhibitor have more than a doubled rate of venous thromboembolism during the subsequent 2 years, according to a large retrospective analysis.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Cardiology News Source Type: news